Frequent apocrine changes in pleomorphic adenoma with malignant transformation: a possible pre-malignant step in ductal carcinoma ex pleomorphic adenoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The most common type of carcinoma ex pleomorphic adenoma (CPA) is histologically equivalent to salivary duct carcinoma, which has an apocrine phenotype. Invasive CPA is often accompanied by non-invasive or in situ carcinoma, an observation that suggests the presence of precursor lesions. The aim of this study was to identify candidate precursor lesions of CPA within pleomorphic adenoma (PA). Methods: Eleven resected cases of CPA with residual PA and 17 cases of PA with atypical changes were subjected to immunohistochemistry (IHC) for p53, human epidermal growth factor receptor 2 (HER2), androgen receptor (AR), pleomorphic adenoma gene 1, gross cystic disease fluid protein-15 (GCDFP-15), and anti-mitochondrial antibody. Results: Invasive or in situ carcinoma cells in all CPAs were positive for AR, GCDFP-15, and HER2. Atypical foci in PAs corresponded to either apocrine or oncocytic changes on the basis of their reactivity to AR, GCDFP-15, and anti-mitochondrial antibody. Atypical cells in PAs surrounding CPAs had an apocrine phenotype without HER2 expression. Conclusions: Our study identified frequent apocrine changes in residual PAs in CPA cases, suggesting a possible precursor role of apocrine changes. We recommend the use of HER2 IHC in atypical PAs, and that clinicians take HER2 positivity into serious consideration.
Abstract
Background: The most common type of carcinoma ex pleomorphic adenoma (CPA) is histologically equivalent to salivary duct carcinoma, which has an apocrine phenotype. Invasive CPA is often accompanied by non-invasive or in situ carcinoma, an observation that suggests the presence of precursor lesions. The aim of this study was to identify candidate precursor lesions of CPA within pleomorphic adenoma (PA). Methods: Eleven resected cases of CPA with residual PA and 17 cases of PA with atypical changes were subjected to immunohistochemistry (IHC) for p53, human epidermal growth factor receptor 2 (HER2), androgen receptor (AR), pleomorphic adenoma gene 1, gross cystic disease fluid protein-15 (GCDFP-15), and anti-mitochondrial antibody. Results: Invasive or in situ carcinoma cells in all CPAs were positive for AR, GCDFP-15, and HER2. Atypical foci in PAs corresponded to either apocrine or oncocytic changes on the basis of their reactivity to AR, GCDFP-15, and anti-mitochondrial antibody. Atypical cells in PAs surrounding CPAs had an apocrine phenotype without HER2 expression. Conclusions: Our study identified frequent apocrine changes in residual PAs in CPA cases, suggesting a possible precursor role of apocrine changes. We recommend the use of HER2 IHC in atypical PAs, and that clinicians take HER2 positivity into serious consideration.
참고문헌 (30)
- 김정원, "Carcinoma ex Pleomorphic Adenoma of the Salivary Glands: Distinct Clinicopathologic Features and Immunoprofiles Between Subgroups According to Cellular Differentiation", Journal of Korean Medical Science, 26(10), pp.1277~1285 (2011), 대한의학회
- Bahrami A, "An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions", Histopathology, 63, pp.250~262 (2013)
- Ohtake S, "Precancerous foci in pleomorphic adenoma of the salivary gland : recognition of focal carcinoma and atypical tumor cells by p53 immunohistochemistry", J Oral Pathol Med, 31, pp.590~597 (2002)
- Di Palma S, "Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma:recognition of focal carcinoma by HER-2", neu and MIB1 immunohistochemistry, 2005, pp.46, 144~152
- Ihrler S, "Intraductal carcinoma is the precursor of carcinoma ex pleomorphic adenoma and is often associated with dysfunctional p53", Histopathology, 51, pp.362~371 (2007)
- Ihrler S, "Histological, immunohistological and molecular characteristics of intraductal precursor of carcinoma ex pleomorphic adenoma support a multistep carcinogenic process", Virchows Arch, 470, pp.601~609 (2017)
- Di Palma S, "Carcinoma ex pleomorphic adenoma, with particular emphasis on early lesions", Head Neck Pathol, 7(Suppl 1), pp.S68~S76 (2013)
- Logasundaram R, "Intracapsular (in situ) carcinoma ex pleomorphic adenoma with unusual clinical and histological features", Eur Arch Otorhinolaryngol, 265, pp.1563~1566 (2008)
- Kapadia SB, "Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma", Mod Pathol, 11, pp.1033~1038 (1998)
- Williams L, "Salivary duct carcinoma : the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression", Am J Surg Pathol, 39, pp.705~713 (2015)
- Nasser SM, "Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors : frequent expression of androgen receptor in a subset of malignant salivary gland tumors", Am J Clin Pathol, 119, pp.801~806 (2003)
- Nakajima Y, "Expressions of androgen receptor and its co-regulators in carcinoma ex pleomorphic adenoma of salivary gland", Pathology, 41, pp.634~639 (2009)
- DeRoche TC, "Immunohistochemical evaluation of androgen receptor, HER-2", neu, and p53 in benign pleomorphic adenomas, 2008, pp.132, 1907~1911
- Schmitt FC, "P53 in breast carcinomas : association between presence of mutation and immunohistochemical expression using a semiquantitative approach", Pathol Res Pract, 194, pp.815~819 (1998)
- Wolff AC, "Human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists clinical practice guideline focused update, 2018, pp.142, 1364~1382
- Chiosea SI, "Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations", Cancer, 122, pp.3136~3144 (2016)
- Katabi N, "Consistent PLAG1 and HMGA2abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts", Hum Pathol, 46, pp.26~33 (2015)
- D’Arcy C, "Apocrine lesions of the breast : part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast", J Clin Pathol, 72, pp.7~11 (2019)
- Jones C, "Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast", Am J Pathol, 158, pp.207~214 (2001)
- D’Arcy C, "Apocrine lesions of the breast : part 1 of a twopart review : benign, atypical and in situ apocrine proliferations of the breast", J Clin Pathol, 72, pp.1~6 (2019)
- Mazoujian G, "Immunohistochemistry of a gross cystic disease fluid protein(GCDFP-15)of the breast : a marker of apocrine epithelium and breast carcinomas with apocrine features", Am J Pathol, 110, pp.105~112 (1983)
- Espinosa CA, "Sclerosing polycystic adenosis of the parotid gland : a systematic review and report of 2 new cases", J Oral Maxillofac Surg, 75, pp.984~993 (2017)
- Gnepp DR, "Salivary gland tumor"wishes"to add to the next WHO Tumor Classification : sclerosing polycystic adenosis, mammary analogue secretory carcinoma, cribriform adenocarcinoma of the tongue and other sites, and mucinous variant of myoepithelioma", Head Neck Pathol, 8, pp.42~49 (2014)
- Skalova A, "Update from the 5th edition of the World Health Organization classification of head and neck tumors:salivary glands", Head Neck Pathol, 16, pp.40~53 (2022)
- Petersson F, "Sclerosing polycystic adenosis of the parotid gland : report of a bifocal, paucicystic variant with ductal carcinoma in situ and pronounced stromal distortion mimicking invasive carcinoma", Head Neck Pathol, 5, pp.188~192 (2011)
- Di Palma S, "Oncocytic change in pleomorphic adenoma : molecular evidence in support of an origin in neoplastic cells", J Clin Pathol, 60, pp.492~499 (2007)
- Triantafyllou A, "Functional histology of salivary gland pleomorphic adenoma : an appraisal", Head Neck Pathol, 9, pp.387~404 (2015)
- Han MW, "Prognostic factors and outcome analysis of salivary duct carcinoma", Auris Nasus Larynx, 42, pp.472~477 (2015)
- Luk PP, "Salivary duct carcinoma: clinicopathologic features, morphologic spectrum, and somatic mutations", Head Neck, 38(Suppl 1), pp.E1838~E1847 (2016)
- Valstar MH, "Malignant transformation of salivary gland pleomorphic adenoma : proof of principle", J Pathol Clin Res, 7, pp.432~437 (2021)